Laparoscopic adjustable gastric banding for weight loss in obese adults:clinical and economic review
Boudreau R, Hodgson A
Record ID 32007000541
English
Authors' objectives:
"This report investigates evidence on the clinical effectiveness and cost-effectiveness of LAGB as compared to RYGB (open and laparoscopic), VBG (open and laparoscopic), lifestyle modification, or control groups." (executive summary)
Authors' results and conclusions:
Patients who undergo LAGB lose a lot of excess weight. This is generally not as much weight as is lost by patients who undergo RYGB (open or laparoscopic) or VBG (open or laparoscopic) procedures. The excess weight that is lost in all surgical groups is enough to reduce obesityrelated comorbidities. In general, very low mortality rates are associated with all bariatric surgeries. LAGB consistently produced fewer short-term complications than RYGB or VBG. Re-operation or conversion to a different bariatric technique may be needed to correct lap band issues (e.g., band erosion).
Limitations of the evidence on LAGB include the lack of long-term studies, the lack of randomized controlled trials, and the poor or not reported follow-up participation rates.
Authors' recommendations:
LAGB has been shown to produce a significant loss of excess weight while maintaining low rates of short-term complications and reducing obesity-related comorbidities. LAGB may not result in the most weight loss but it may be an option for bariatric patients who prefer or who are better suited to undergo less invasive and reversible surgery with lower perioperative complication rates.
One caution with LAGB is the uncertainty about whether the low complication rate extends past three years, given a possibility of increased band-related complications (e.g., erosion, slippage) requiring re-operation.
Authors' methods:
Systematic review
Details
Project Status:
Completed
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Gastroplasty
- Weight Loss
- Obesity
- Obesity, Morbid
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.